Beijing Scitop Bio-tech Co Ltd
SZSE:300858
Intrinsic Value
Beijing Scitop Bio-Tech Co., Ltd. develops, produces, and sells probiotic lactic acid bacteria and related products and provides a complete set of product solutions. [ Read More ]
The intrinsic value of one
Beijing Scitop Bio-tech Co Ltd
stock under the Base Case scenario is
12.44
CNY.
Compared to the current market price of 16.98 CNY,
Beijing Scitop Bio-tech Co Ltd
is
Overvalued by 27%.
Beijing Scitop Bio-tech Co Ltd's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
Beijing Scitop Bio-tech Co Ltd or that its price is influenced by factors unrelated to fundamentals.
Beijing Scitop Bio-tech Co Ltd's market capitalization is 4.5B CNY.
Beijing Scitop Bio-tech Co Ltd stock price is 16.98 CNY.
Beijing Scitop Bio-tech Co Ltd stock (12.44 CNY) is 27% less than its price (16.98 CNY).
Beijing Scitop Bio-tech Co Ltd stock price (16.98 CNY) is 14% less than its DCF Value (19.75 CNY). Open DCF Valuation
Beijing Scitop Bio-tech Co Ltd stock (5.13 CNY) is 70% less than its price (16.98 CNY). Open Relative Valuation
Beijing Scitop Bio-tech Co Ltd has upside potential of 6% compared to the average analyst price target.
Open Wall St Estimates
Beijing Scitop Bio-tech Co Ltd has positive three-year average ROE (Return on Equity): 10%. The company is efficient at transforming stockholders' equity into net income.
Beijing Scitop Bio-tech Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 5%.
Beijing Scitop Bio-tech Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 5%.
Beijing Scitop Bio-tech Co Ltd has negative Free Cash Flow for the last twelve months.
Beijing Scitop Bio-tech Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 15% to 5%.
Beijing Scitop Bio-tech Co Ltd has positive three-year average ROIC (Return on Invested Capital): 16%. The company is efficient at using invested capital to generate operating income.
Beijing Scitop Bio-tech Co Ltd's Revenue has been falling by 7% per year for the last 3 years.
Beijing Scitop Bio-tech Co Ltd's Revenue has dropped by 19% over the past 12 months.
Beijing Scitop Bio-tech Co Ltd has positive Operating Income for the last twelve months.
Beijing Scitop Bio-tech Co Ltd's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 24% to 5%.
Beijing Scitop Bio-tech Co Ltd has positive Net Income for the last twelve months.
Beijing Scitop Bio-tech Co Ltd has positive Gross Profit for the last twelve months.
Beijing Scitop Bio-tech Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.01.
Beijing Scitop Bio-tech Co Ltd's short-term assets (956m CNY) exceed its short-term liabilties (59m CNY).
Beijing Scitop Bio-tech Co Ltd's long-term assets (2B CNY) exceed its long-term liabilties (77m CNY).
Beijing Scitop Bio-tech Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (341m CNY) than debt (10m CNY).
Beijing Scitop Bio-tech Co Ltd's Altman Z-Score is very high and is equal to 37.23.
Valuation Backtest
Beijing Scitop Bio-tech Co Ltd
Run backtest to discover the historical profit from buying and selling
Beijing Scitop Bio-tech Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Beijing Scitop Bio-tech Co Ltd
Balance Sheet Decomposition
Beijing Scitop Bio-tech Co Ltd
| Current Assets | 955.6m |
| Cash & Short-Term Investments | 340.8m |
| Receivables | 81.8m |
| Other Current Assets | 533m |
| Non-Current Assets | 854.5m |
| Long-Term Investments | 2.6m |
| PP&E | 375.1m |
| Intangibles | 53m |
| Other Non-Current Assets | 423.9m |
| Current Liabilities | 58.6m |
| Accounts Payable | 16.1m |
| Accrued Liabilities | 15.7m |
| Other Current Liabilities | 26.8m |
| Non-Current Liabilities | 18.5m |
| Long-Term Debt | 9.9m |
| Other Non-Current Liabilities | 8.6m |
Earnings Waterfall
Beijing Scitop Bio-tech Co Ltd
|
Revenue
|
286.1m
CNY
|
|
Cost of Revenue
|
-133.6m
CNY
|
|
Gross Profit
|
152.5m
CNY
|
|
Operating Expenses
|
-84.9m
CNY
|
|
Operating Income
|
67.6m
CNY
|
|
Other Expenses
|
24.3m
CNY
|
|
Net Income
|
91.9m
CNY
|
Free Cash Flow Analysis
Beijing Scitop Bio-tech Co Ltd
Profitability Score
Profitability Due Diligence
Beijing Scitop Bio-tech Co Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Beijing Scitop Bio-tech Co Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Beijing Scitop Bio-tech Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Beijing Scitop Bio-tech Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Beijing Scitop Bio-tech Co Ltd
According to Wall Street analysts, the average 1-year price target for
Beijing Scitop Bio-tech Co Ltd
is 18.02 CNY
with a low forecast of 17.85 CNY and a high forecast of 18.55 CNY.
Shareholder Return
Price
Beijing Scitop Bio-tech Co Ltd
| Average Annual Return | 27.5% |
| Standard Deviation of Annual Returns | 45.82% |
| Max Drawdown | -62% |
| Market Capitalization | 4.5B CNY |
| Shares Outstanding | 263 495 118 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Beijing Scitop Bio-tech Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Beijing Scitop Bio-Tech Co., Ltd. develops, produces, and sells probiotic lactic acid bacteria and related products and provides a complete set of product solutions. The company is headquartered in Beijing, Beijing and currently employs 226 full-time employees. The company went IPO on 2020-07-27. The firm's main products include compound food additives, edible probiotic products, animal and plant microecological preparations and others. The firm mainly conducts its businesses within the China market.
Contact
IPO
Employees
Officers
The intrinsic value of one
Beijing Scitop Bio-tech Co Ltd
stock under the Base Case scenario is
12.44
CNY.
Compared to the current market price of 16.98 CNY,
Beijing Scitop Bio-tech Co Ltd
is
Overvalued by 27%.
You don't have any saved screeners yet
